Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.35) Per Share (AUP)

Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Cantor Fitzgerald decreased their FY2017 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a report released on Monday. Cantor Fitzgerald analyst E. Piros now anticipates that the company will post earnings per share of ($1.35) for the year, down from their previous forecast of ($1.27). Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($0.97) EPS.

ILLEGAL ACTIVITY WARNING: “Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.35) Per Share (AUP)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/24/aurinia-pharmaceuticals-inc-expected-to-earn-fy2017-earnings-of-1-35-per-share-aup.html.

Separately, Seaport Global Securities reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th.

Shares of Aurinia Pharmaceuticals (AUP) opened at C$6.88 on Wednesday. Aurinia Pharmaceuticals has a 1 year low of C$2.75 and a 1 year high of C$14.17.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

What are top analysts saying about Aurinia Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aurinia Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit